Cyclerion Therapeutics (NASDAQ:CYCN) Shares Down 0.9%

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Rating) traded down 0.9% during mid-day trading on Wednesday . The stock traded as low as $4.25 and last traded at $4.31. 22,759 shares traded hands during trading, a decline of 5% from the average session volume of 23,926 shares. The stock had previously closed at $4.35.

Cyclerion Therapeutics Stock Performance

The firm’s 50-day simple moving average is $6.81 and its 200-day simple moving average is $10.92.

Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) last posted its quarterly earnings results on Wednesday, March 22nd. The company reported ($3.20) earnings per share (EPS) for the quarter. The business had revenue of $0.61 million for the quarter.

Institutional Trading of Cyclerion Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in Cyclerion Therapeutics by 0.9% during the first quarter. Geode Capital Management LLC now owns 592,237 shares of the company’s stock valued at $257,000 after buying an additional 5,500 shares during the period. Prelude Capital Management LLC boosted its holdings in shares of Cyclerion Therapeutics by 29.2% during the first quarter. Prelude Capital Management LLC now owns 100,255 shares of the company’s stock worth $111,000 after purchasing an additional 22,672 shares during the period. Mackenzie Financial Corp purchased a new stake in shares of Cyclerion Therapeutics during the first quarter worth about $28,000. Virtu Financial LLC purchased a new stake in shares of Cyclerion Therapeutics during the fourth quarter worth about $32,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Cyclerion Therapeutics during the second quarter worth about $29,000. 58.50% of the stock is currently owned by hedge funds and other institutional investors.

Cyclerion Therapeutics Company Profile

(Get Rating)

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate.